Cat. No. |
Product Name |
Information |
PC-60395 |
Trilaciclib
CDK4/6 inhibitor
|
Trilaciclib (G1T28) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
PC-60329 |
NVP-2
CDK9 inhibitor
|
NVP-2 is a potent, selective, ATP-competitive CDK9 inhibitor with IC50 of <0.514 nM (CDK9/CyclinT). |
PC-70177 |
VMY-1-103
CDK inhibitor
|
VMY-1-103 is a dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. |
PC-70170 |
GW-8510
CDK2 inhibitor
|
GW-8510 (GW8510) is a potent, selective inhibitor of CDK2 with IC50 of 10 nM. |
PC-70116 |
NU-6027
CDK1/2 inhibitor
|
NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively. |
PC-70115 |
NU6102
CDK2 inhibitor
|
NU6102 is a potent CDK1 and CDK2 inhibitor with IC50 of 9.5 nM and 5.4 nM against CDK1/cyclinB and CDK2/cyclinA3 respectively. |
PC-60298 |
MSC2530818
CDK8 inhibitor
|
MSC-2530818 (MSC 2530818, MSC2530818) is a potent, selective, and orally bioavailable CDK8 inhibitor with IC50 of 2.6 nM. |
PC-60188 |
Olomoucine
CDK inhibitor
|
Olomoucine is a potent, ATP-competetive CDKs inhibitor with IC50 of 7, 7, 7, 3 uM for Cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk/p35 kinase. |
PC-42103 |
M2I-1
Mad2 inhibitor
|
M2I-1 is the first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20. |
PC-45559 |
NU-6300
CDK2 inhibitor
|
NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM. |
PC-45599 |
NU-2058
CDK1/2 inhibitor
|
NU-2058 is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively. |
PC-43435 |
TAME
APC/C inhibitor
|
TAME (Tosyl-L-arginine methyl ester) is a small molecule anaphase-promoting complex/cyclosome (APC/C) inhibitor that binds to the APC preferentially suppresses APC/C(Cdc20) rather than APC/C(Cdh1). |